Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Review, H2 2016’, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer)

The report reviews pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics and enlists all their major and minor projects

The report assesses Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ArQule, Inc.

EnGeneIC Ltd

Exelixis, Inc.

Merck KGaA

Millendo Therapeutics, Inc.

Orphagen Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 6

Therapeutics Development 7

Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 7

Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis 8

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Development by Companies 9

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Investigation by Universities/Institutes 10

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Development by Companies 13

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Investigation by Universities/Institutes 14

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development 15

ArQule, Inc. 15

EnGeneIC Ltd 16

Exelixis, Inc. 17

Merck KGaA 18

Millendo Therapeutics, Inc. 19

Orphagen Pharmaceuticals, Inc. 20

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

ARQ-087 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

ATR-101 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

avelumab - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

cabozantinib s-malate - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

TargomiRs - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects 62

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products 63

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones 64

Featured News & Press Releases 64

Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016 64

Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015 64

Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers 65

Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma 66

Appendix 67

Methodology 67

Coverage 67

Secondary Research 67

Primary Research 67

Expert Panel Validation 67

Contact Us 67

Disclaimer 68

List of Tables

List of Tables

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2016 7

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by ArQule, Inc., H2 2016 15

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by EnGeneIC Ltd, H2 2016 16

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Exelixis, Inc., H2 2016 17

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Merck KGaA, H2 2016 18

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Millendo Therapeutics, Inc., H2 2016 19

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Dormant Projects, H2 2016 62

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Discontinued Products, H2 2016 63

List of Figures

List of Figures

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2016 7

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Top 10 Targets, H2 2016 22

Number of Products by Stage and Top 10 Targets, H2 2016 22

Number of Products by Top 10 Mechanism of Actions, H2 2016 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports